Aurora Financial JournalEgetis Therapeutics AB (publ) (EGTX.ST)
Nasdaq Stockholm · Financial statements, TTM figures and earnings dates
In fiscal year 2024 (ended December 31, 2024), Egetis Therapeutics AB (publ) reported revenue of SEK 46.1M and net income of −SEK 343.6M. Annual financial statements are available for fiscal years 2021 to 2024, taken from the company's ESEF annual reports (IFRS).
Open interactive financials →Key financials
| SEK | FY2024 2024-12-31 | FY2023 2023-12-31 | FY2022 2022-12-31 | FY2021 2021-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | SEK 46.1M | SEK 57.6M | SEK 22.6M | SEK 38.2M |
| Gross profit | SEK 34.5M | SEK 46.6M | SEK 16.3M | SEK 30.3M |
| Operating income | −SEK 329.4M | −SEK 324.8M | −SEK 198.1M | −SEK 105.7M |
| Net income | −SEK 343.6M | −SEK 326.9M | −SEK 193.8M | −SEK 104.5M |
| Diluted EPS | −SEK 1.10 | −SEK 1.30 | −SEK 1.00 | −SEK 0.60 |
| Cash flow | ||||
| Operating cash flow | −SEK 227.9M | −SEK 278.4M | −SEK 173.5M | −SEK 130.1M |
| Capital expenditure | SEK 0 | SEK 0 | SEK 0 | SEK 200.0K |
| Free cash flow | −SEK 227.9M | −SEK 278.4M | −SEK 173.5M | −SEK 130.3M |
| Balance sheet | ||||
| Cash and equivalents | SEK 351.0M | SEK 303.3M | SEK 127.7M | SEK 144.0M |
| Total assets | SEK 792.3M | SEK 760.2M | SEK 561.1M | SEK 569.3M |
| Total liabilities | SEK 299.4M | SEK 214.6M | SEK 54.9M | SEK 42.3M |
| Total debt | SEK 114.2M | SEK 108.6M | SEK 0 | – |
| Shareholders' equity | SEK 492.9M | SEK 545.6M | SEK 506.2M | SEK 527.0M |
TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in SEK as reported; per-share data adjusted for stock splits.
Annual reports
More on the interactive page
The full EGTX.ST page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.
Open EGTX.ST financials →